Stock Track | Surgery Partners Plunges 24.37% on Q4 Earnings Miss, Margin Pressure and Weak 2026 Outlook

Stock Track

Mar 03

Surgery Partners' stock experienced a significant 24.37% plunge during intraday and after-hours trading, following the release of its fourth quarter 2025 financial results.

The sharp decline was primarily driven by a substantial earnings miss, with Q4 adjusted EPS of $0.12 falling 60% short of the analyst consensus estimate of $0.30. Furthermore, the company reported Q4 adjusted EBITDA of $156.9 million, which missed estimates of $169.2 million, indicating significant margin pressure that impacted full-year performance according to company statements.

Adding to investor concerns, Surgery Partners provided 2026 revenue guidance in the range of $3.35 billion to $3.45 billion, which came in below the consensus estimate of $3.56 billion. While the company announced a $200 million share repurchase program and reported Q4 revenue of $885 million that beat estimates, the profitability shortfalls and cautious outlook overshadowed these positive developments.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1132337179"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1132337179\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1132337179?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-03 10:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132337179","market":"nz","top_or_hot":-1,"title":"Stock Track | Surgery Partners Plunges 24.37% on Q4 Earnings Miss, Margin Pressure and Weak 2026 Outlook","media":"Stock Track","content":"<p>Surgery Partners' stock experienced a significant 24.37% plunge during intraday and after-hours trading, following the release of its fourth quarter 2025 financial results.</p><p>The sharp decline was primarily driven by a substantial earnings miss, with Q4 adjusted EPS of $0.12 falling 60% short of the analyst consensus estimate of $0.30. Furthermore, the company reported Q4 adjusted EBITDA of $156.9 million, which missed estimates of $169.2 million, indicating significant margin pressure that impacted full-year performance according to company statements.</p><p>Adding to investor concerns, Surgery Partners provided 2026 revenue guidance in the range of $3.35 billion to $3.45 billion, which came in below the consensus estimate of $3.56 billion. While the company announced a $200 million share repurchase program and reported Q4 revenue of $885 million that beat estimates, the profitability shortfalls and cautious outlook overshadowed these positive developments.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Surgery Partners Plunges 24.37% on Q4 Earnings Miss, Margin Pressure and Weak 2026 Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Surgery Partners Plunges 24.37% on Q4 Earnings Miss, Margin Pressure and Weak 2026 Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-03 10:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Surgery Partners' stock experienced a significant 24.37% plunge during intraday and after-hours trading, following the release of its fourth quarter 2025 financial results.</p><p>The sharp decline was primarily driven by a substantial earnings miss, with Q4 adjusted EPS of $0.12 falling 60% short of the analyst consensus estimate of $0.30. Furthermore, the company reported Q4 adjusted EBITDA of $156.9 million, which missed estimates of $169.2 million, indicating significant margin pressure that impacted full-year performance according to company statements.</p><p>Adding to investor concerns, Surgery Partners provided 2026 revenue guidance in the range of $3.35 billion to $3.45 billion, which came in below the consensus estimate of $3.56 billion. While the company announced a $200 million share repurchase program and reported Q4 revenue of $885 million that beat estimates, the profitability shortfalls and cautious outlook overshadowed these positive developments.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SGRY","symbol_name":"Surgery Partners, Inc.","start_time":0,"source_url":"","article_id":"1132337179","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132337179","pubTimestamp":1772506637,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Surgery Partners' stock experienced a significant 24.37% plunge during intraday and after-hours trading, following the release of its fourth quarter 2025 financial results.The sharp decline was...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SGRY":"Surgery Partners, Inc."},"translate_title":"股票追踪|Surgery Partners因第四季度盈利未达预期、利润率压力和2026年前景疲软而暴跌24.37%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SGRY":1},"content_text":"Surgery Partners' stock experienced a significant 24.37% plunge during intraday and after-hours trading, following the release of its fourth quarter 2025 financial results.The sharp decline was primarily driven by a substantial earnings miss, with Q4 adjusted EPS of $0.12 falling 60% short of the analyst consensus estimate of $0.30. Furthermore, the company reported Q4 adjusted EBITDA of $156.9 million, which missed estimates of $169.2 million, indicating significant margin pressure that impacted full-year performance according to company statements.Adding to investor concerns, Surgery Partners provided 2026 revenue guidance in the range of $3.35 billion to $3.45 billion, which came in below the consensus estimate of $3.56 billion. While the company announced a $200 million share repurchase program and reported Q4 revenue of $885 million that beat estimates, the profitability shortfalls and cautious outlook overshadowed these positive developments.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}